[Efficacy analysis of CHAG priming regimen as induction therapy for newly diagnosed acute myelogenous leukemia].
作者信息
Hao Qianmeng, Wei Xudong, Yin Qingsong, Mi Ruihua, Yuan Fangfang, Ai Hao, Wang Ping, Chen Lin, Song Yongping
机构信息
Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University; Henan Cancer Hospital. Zhengzhou 450008, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2015 Jan;36(1):68-9. doi: 10.3760/cma.j.issn.0253-2727.2015.01.018.
Abstract
摘要
相似文献
1
[Efficacy analysis of CHAG priming regimen as induction therapy for newly diagnosed acute myelogenous leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2015 Jan;36(1):68-9. doi: 10.3760/cma.j.issn.0253-2727.2015.01.018.
2
[Comparative evaluation of CHAG and CAG priming regimen for treatment of refractory and relapsed acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2012 Jun;33(6):484-6.
3
CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination.
Leuk Lymphoma. 2013 Oct;54(10):2291-3. doi: 10.3109/10428194.2013.772295. Epub 2013 Mar 8.
4
[Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008 Mar;33(3):245-51.
5
SNPing away to individualize induction therapy for acute myelogenous leukemia.
Leuk Lymphoma. 2016;57(4):742-3. doi: 10.3109/10428194.2015.1136743. Epub 2016 Jan 19.
6
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Leuk Res. 2016 Mar;42:82-7. doi: 10.1016/j.leukres.2015.12.013. Epub 2016 Jan 2.
7
Granulocyte colony stimulating factor priming chemotherapy is more effective than standard chemotherapy as salvage therapy in relapsed acute myeloid leukemia.
Med Clin (Barc). 2018 Nov 9;151(9):339-344. doi: 10.1016/j.medcli.2017.11.027. Epub 2017 Dec 29.
8
[Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Jun;26(3):743-749. doi: 10.7534/j.issn.1009-2137.2018.03.019.
9
Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Leuk Lymphoma. 2015 Jun;56(6):1691-7. doi: 10.3109/10428194.2014.963074. Epub 2014 Nov 3.
10
In vitro inhibition of aromatase by the enantiomers of aminoglutethimide and analogs.
Chirality. 1994;6(8):623-6. doi: 10.1002/chir.530060804.
本文引用的文献
1
CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination.
Leuk Lymphoma. 2013 Oct;54(10):2291-3. doi: 10.3109/10428194.2013.772295. Epub 2013 Mar 8.
2
Progress and strategies for patients with relapsed and refractory acute myeloid leukemia.
Curr Opin Hematol. 2007 Mar;14(2):130-7. doi: 10.1097/MOH.0b013e32801684ef.
3
Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
Ann Hematol. 2006 Apr;85(4):250-6. doi: 10.1007/s00277-005-0066-0. Epub 2006 Jan 14.
4
Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells.
Chin Med J (Engl). 2005 Mar 20;118(6):487-92.
5
6
Aclarubicin induces differentiation of leukemic progenitors in myelodysplastic syndrome cooperating with granulocyte colony-stimulating factor.
Leuk Res. 2000 Mar;24(3):243-8. doi: 10.1016/s0145-2126(99)00175-7.
7
Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells.
Exp Hematol. 1999 Feb;27(2):259-65. doi: 10.1016/s0301-472x(98)00041-1.
Zotero 插件